The implications of a growing evidence base for drug use in elderly patients. Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients

British Journal of Clinical Pharmacology

Volumn 61, Issue 5, 2006, Pages 502-512

  Mangoni, A A ^a,c   Jackson, S H D ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Cardiovascular risk; Congestive cardiac failure; Elderly patients; Randomized controlled trials

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; INDAPAMIDE; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TRANDOLAPRIL; VALSARTAN;

AGED; ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRY COUGH; EDEMA; EVIDENCE BASED MEDICINE; GERIATRIC PATIENT; HEADACHE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPOTENSION; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33646232747     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02610.x     Document Type: Review

References (36)

1. Garg R Yusuf S Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials JAMA 1995 273 1450 6
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 1987 316 1429 35
3. Gambassi G Lapane KL Sgadari A Carbonin P Gatsonis C Lipsitz LA Mor V Bernabei R Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology Arch Intern Med 2000 160 53 60
4. Pfeffer MA Braunwald E Moye LA Basta L Brown EJ Jr Cuddy TE Davis BR Geltman EM Goldman S Flaker GC Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators N Engl J Med 1992 327 669 77
5. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet 1993 342 821 8
6. GISSI- Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico Lancet 1994 343 1115 22
7. Kober L Torp-Pedersen C Carlsen JE Bagger H Eliasen P Lyngborg K Videback J Cole DS Auclert L Pauly NC A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group N Engl J Med 1995 333 1670 6
8. ISIS- (Fourth International Study of Infarct Survival) Collaborative Group. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction Lancet 1995 345 669 85
9. Hansson L Lindholm LH Ekbom T Dahlof B Lanke J Schertsen B Wester PO Hedner T de Faire U Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study Lancet 1999 354 1751 6
10. Yusuf S Sleight P Pogue J Bosch J Davies R Dagenais G Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 2000 342 145 53
11. The Progress Study. Randomised trial of a perindopril-based blood-pressure-Iowering regimen among 6105 individuals with previous stroke or transient ischaemic attack Lancet 2001 358 1033 41
12. Fox KM Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 2003 362 782 8
13. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic JAMA 2002 288 2981 97
14. Wing LM Reid CM Ryan P Beilin LJ Brown MA Jennings GL Johnston CI McNeil JJ Macdonald GJ Marley JE Morgan TO West MJ A comparison of outcomes with angiotensin-converting - enzyme inhibitors and diuretics for hypertension in the elderly N Engl J Med 2003 348 583 92
15. Heckman GA Misiaszek B Merali F Turpie ID Patterson CJ Flett N McKelvie RS Management of heart failure in Canadian long-term care facilities Can J Cardiol 2004 20 963 9
16. Manyemba J Mangoni AA Pettingale KW Jackson SH Determinants of failure to prescribe target doses of angiotensin-converting enzyme inhibitors for heart failure Eur J Heart Fail 2003 5 693 6
17. Masoudi FA Rathore SS Wang Y Havranek EP Curtis JP Foody JM Krumholz HM National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction Circulation 2004 110 724 31
18. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N Engl J Med 1992 327 685 91
19. Cleland JG Tendera M Adamus J Freemantle N Gray CS Lye M O'Mahony D Polanski L Taylor J Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP Investigators Eur J Heart Fail 1999 1 211 7
20. Pitt B Segal R Martinez FA Meurers G Cowley AJ Thomas I Deedwania PC Ney DE Snaveley DB Chang PI Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet 1997 349 747 52
21. Pitt B Poole-Wilson PA Segal R Martinez FA Dickstein K Camm AJ Konstam MA Riegger G Klinger GH Neaton J Sharma D Thiyagarajan B Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II Lancet 2000 355 1582 7
22. Cohn JN Tognoni G A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 2001 345 1667 75
23. McMurray JJ Ostergren J Swedberg K Granger CB Held P Michelson EL Olofsson B Yusuf S Pfeffer MA Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 2003 362 767 71
24. Pfeffer MA McMurray JJ Velazquez EJ Rouleau JL Kober L Maggioni AP Solomon SD Swedberg K Van de WF White H Leimberger JD Henis M Edwards S Zelenkofske S Sellers MA Califf RM Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 2003 349 1893 906
25. Baruch L Heywood T KH. Efficacy of valsartan in elderly heart failure patients in Val-HeFT Circulation 2004 106 Suppl II :): S685.
26. Granger CB McMurray JJ Yusuf S Held P Michelson EL Olofsson B Ostergren J Pfeffer MA Swedberg K Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 2003 362 772 6
27. Yusuf S Pfeffer MA Swedberg K Granger CB Held P McMurray JJ Michelsen EL Olofsson B Ostergren J Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 2003 362 777 81
28. Pfeffer MA Swedberg K Granger CB Held P McMurray JJ Michelson EL Olofsson B Ostergren J Yusuf S Pocock S Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 2003 362 759 66
29. Dickstein K Kjekshus J Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Lancet 2002 360 752 60
30. Burnier M Angiotensin II type 1 receptor blockers Circulation 2001 103 904 12
31. Dahlof B Devereux RB Kjeldsen SE Julius S Beevers G de Faire U Fyhrquist F Ibsen H Kristiansson K Lederballe-Pedersen O Lindholm LH Nieminen MS Omvik P Oparil S Wedel H Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 2002 359 995 1003
32. Okin PM Devereux RB Jern S Kjeldsen SE Julius S Nieminen MS Snapinn S Harris KE Aurup P Edelman JM Dahlof B Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study Circulation 2003 108 684 90
33. Lithell H Hansson L Skoog I Elmfedt D Hofman A Olofsson B Trenkwalder P Zanchetti A The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial J Hypertens 2003 21 875 86
34. Papademetriou V Farsang C Elmfeldt D Hofman A Lithell H Olofsson B Skoog I Trenkwalder P Zanchetti A Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE) J Am Coll Cardiol 2004 44 1175 80
35. Julius S Kjeldsen SE Weber M Brunner HR Ekman S Hansson L Hua T Laragh J McInnes GT Mitchell L Plat F Schork A Smith B Zanchetti A Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 2004 363 2022 31
36. Carlberg B Samuelsson O Lindholm LH Atenolol in hypertension: is it a wise choice? Lancet 2004 364 1684 9